Oncology

WU-CART-007 has been granted fast track, rare pediatric disease, and orphan drug designations.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Ofra-vec continues to be evaluated in phase 2 trials for glioblastoma and colorectal cancer.

Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.

Lauren Veltri, MD Director, WVU Cancer Institute Hematopoietic Malignancy and Cellular Therapy Program, discussed the recent FACT accreditation.

Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.

Review top news and interview highlights from the week ending July 15, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SCG101 will be evaluated in trials across China, Singapore, and the US.

The chief program officer of the Alliance for Cancer Gene Therapy discussed the work the nonprofit is doing.

The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.

A phase 1 trial has completed enrollment in its first cohort and is now enrolling the second.

The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.

Legend Biotech seeks to prioritize other product candidates in its pipeline.

The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.

The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.

The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending July 1, 2022.

The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.

The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.